AstraZeneca: Tagrisso (osimertinib) With the Addition of Chemotherapy Showed Favorable Trend in Overall Survival in EGFR-Mutated Advanced Lung Cancer With Further Follow Up in FLAURA2 Phase III Trial
March 22, 2024
March 22, 2024
WILMINGTON, Delaware, March 22 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release (TNSres):
Results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) . . .
Results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) . . .